Related Experiment Video
Updated: Jul 24, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Coexisting Genomic Alterations in Risk Stratification of KRASG12C-Mutated Non-Small Cell Lung Cancer
Sarina Z W Heng1,2, Regina Hoo1,2, Daniel S W Tan1,2,3,4
1Cancer and Therapeutics Research Laboratory, National Cancer Center Singapore, Singapore.
Summary:
Negrao and colleagues showed that coalterations in three genes-KEAP1, SMARCA4, and CDKN2A- correlated to poor clinical outcomes in patients with KRASG12C-mutated non-small cell lung cancer treated with sotorasib or adagrasib. Their study highlights how pooling high-resolution real-world genomic data with clinical outcomes can potentially facilitate risk-stratified precision therapies. See related article by Negrao et al., p. 1556 (2).
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018